China
Africa
Explore chapters and articles related to this topic
Repositioning Antiviral Drugs as a Rapid and Cost-Effective Approach to Discover Treatment against SARS-CoV-2 Infection
Published in Hajiya Mairo Inuwa, Ifeoma Maureen Ezeonu, Charles Oluwaseun Adetunji, Emmanuel Olufemi Ekundayo, Abubakar Gidado, Abdulrazak B. Ibrahim, Benjamin Ewa Ubi, Medical Biotechnology, Biopharmaceutics, Forensic Science and Bioinformatics, 2022
Omotayo Opemipo Oyedara, Folasade Muibat Adeyemi, Charles Oluwaseun Adetunji, Temidayo Oluyomi Elufisan
Sofosbuvir, an inhibitor of polymerase in hepatitis C virus, has been suggested as a promising drug for the treatment of COVID-19 (Sali et al. 2020). Furthermore, combination therapy using sofosbuvir and daclatasvir was reported to possibly increase the efficacy of sofosbuvir (Sadeghi et al. 2020; Simmons et al. 2021). From molecular docking analysis reports, galidesivir bind strongly to the catalytic site of SARS-CoV-2 RNA polymerase (Ataei and Hosseinjani 2020; Elfiky, 2020), hence making it a good candidate drug for COVID-19 treatment.
Nanomaterials against pathogenic viruses: greener and sustainable approaches
Published in Inorganic and Nano-Metal Chemistry, 2020
Ghazaleh Jamalipour Soufi, Siavash Iravani
The design of amino-decorated mesoporous silica NPs for sustained and controlled delivery of sofosbuvir (a medication used to treat hepatitis C) with enhanced bioavailability was reported.[47] It was observed that these functionalized mesoporous silica NPs (∼196 nm) entrapped 29.13% sofosbuvir in the pores, and exhibited an improved thermal stability. Amino-decorated mesoporous silica NPs showed Fickian diffusion controlled sofosbuvir release as compared with non-functionalized and polyvinyl alcohol (PVA) grafted mesoporous silica NPs. Importantly, a 2-fold higher bioavailability of sofosbuvir was obtained in rats in comparison with sofosbuvir alone, and the Tmax was delayed 3-times demonstrating a sustained release of sofosbuvir.[47]
A cost-effectiveness analysis of the use of safety-engineered syringes in reducing HBV, HCV, and HIV burden in Egypt
Published in Expert Review of Medical Devices, 2019
Aya Mostafa, Gihan Hamdy Elsisi
The diagnosed percentage of HCV and HBV infections in Egypt was derived from Egypt Health Issues Survey 2015 published by the MoHP [9], while for HIV infection, the percentage was derived from HIV and AIDS estimates in Egypt, country factsheet published by United Nations Program on HIV/AIDS (UNAIDS) [17]. The treatment efficacy for the sofosbuvir + daclatasvir (SOF+DCV) regimen was obtained from national hepatitis C treatment program data, prospectively collected from 18,378 viremic HCV patients with chronic liver disease, mostly infected with Genotype 4, started treatment with SOF+DCV with or without ribavirin in real-world settings [19], while for entecavir, first-line treatment for HBV infection, the treatment efficacy was derived from a phase 3 double-blind trial randomly assigned 648 patients with negative hepatitis B early antigen (HBeAg) who had not previously been treated, compared entecavir versus lamivudine for a minimum of 52 weeks [25].The treatment efficacy of antiretroviral therapy (ART) in HIV infection was derived from systematic review and meta-analysis of 114 initial ART studies, in adults, of ≥48 weeks duration with up to 144 weeks’ follow-up [22].
Synthesis and characterization of new bis(fluoroalkyl) phosphoramidates bearing sulfoximine groups
Published in Journal of Sulfur Chemistry, 2021
Hanen Mechi, M.A.K. Sanhoury, F. Laribi, M. T. Ben Dhia
Organophosphorus compounds are increasingly attracting considerable attention due to their large applications in different fields [1–5]. In particular, phosphoramidates have been widely used in medicinal chemistry as potential prodrugs [6–11] and as transition state analogs of amide bond hydrolysis [12–14]. For instance, nucleoside phosphoramidate prodrugs such as MK-3682 are tested as potential drugs due to their pronounced antiviral and antitumor properties and in 2013, the FDA approved Sofosbuvir for treating infection with hepatitis C virus [6–8]. In asymmetric synthesis, phosphoramidates have also been used as efficient organocatalysts [15,16].